Internal Medicine News - Gemifloxacin mesylate available
December 1, 2004 -- Factive (gemifloxacin mesylate) is available for the treatment of acute bacterial exacerbations of chronic bronchitis and mild to moderate...
Business Wire - FACTIVE, gemifloxacin mesylate, Tablets Receive Marketing Approval from Health Canada; FDA-Approved Fluoroquinolone Being Readied for Launch in U.S
March 11, 2004 -- Business Editors/Health/Medical Writers WALTHAM, Mass.--(BUSINESS WIRE)--March 11, 2004 Genome Therapeutics Corp. (Nasdaq: GENE) has received...
Business Wire - Oscient Pharmaceuticals to Participate in the Rodman & Renshaw 10th Annual Healthcare Conference
November 5, 2008 -- WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Rodman & Renshaw 10th Annual Healthcare Conference...
Business Wire - Oscient Pharmaceuticals Reports Third Quarter 2008 Financial Results
November 4, 2008 -- -- Total revenues increase more than 40% from Q3 2007 -- - Conference call with senior management scheduled for 8:30 AM today - WALTHAM, Mass. --...
Business Wire - Oscient Pharmaceuticals to Participate in the BMO Capital Markets Focus on Healthcare Conference
August 1, 2008 -- WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the BMO Capital Markets Focus on Healthcare Conference on...
Business Wire - Regulatory Filing for FACTIVE Tablets Submitted in Europe
May 7, 2008 -- Oscient Pharmaceuticals' partner, Menarini Group, seeks marketing approval for fluoroquinolone antibiotic WALTHAM, Mass. -- Oscient Pharmaceuticals...
Business Wire - Oscient Pharmaceuticals to Participate in the Roth Capital Partners 20th Annual OC Growth Conference
February 14, 2008 -- WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Roth Capital Partners 20th Annual OC Growth Conference...
Business Wire - Webcast Alert: Oscient Pharmaceuticals to Participate in the BIO CEO & Investor Conference
February 7, 2008 -- WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (NASDAQ:OSCI) will participate in the BIO CEO & Investor Conference on Wednesday, February...
Business Wire - Oscient Pharmaceuticals Records 2007 Revenues of $80 Million; Reports Financial Results for Fourth Quarter and Fiscal Year 2007
February 6, 2008 -- Conference call with senior management scheduled for 8:30 AM today WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today...
Business Wire - Oscient Pharmaceuticals Provides Preliminary Revenue Results for Fourth Quarter and Fiscal Year 2007
January 14, 2008 -- 2007 Revenues Increase to Approximately $80 Million from $46 Million in 2006; ANTARA([R]) Acquisition Catalyst for Growth WALTHAM, Mass. -- Oscient...
